William Blair analyst Matt Phipps reiterated an Outperform rating on Compass Therapeutics (NASDAQ: CMPX)The analyst commented, "Before the markets ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE